The presence of aflatoxin B1-FAPY adduct and human papilloma virus in cervical smears from cancer patients in Mexico

Food Additives and Contaminants - Part A

Volumn 29, Issue 2, 2012, Pages 258-268

  Carvajal, Magda ^a   Berumen, Jaime ^b   Guardado Estrada, Mariano ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Cervical cancer; HPV; HPV16; HPV18; Human papillomavirus

Indexed keywords

AFLATOXINS; DISEASES; DNA; DNA SEQUENCES; ONCOGENIC VIRUSES; POLYMERASE CHAIN REACTION; TUMORS;

AVERAGE CONCENTRATION; CERVICAL CANCERS; FORMAMIDOPYRIMIDINE; HPV16; HPV18; HUMAN PAPILLOMAVIRUS; LIMIT OF QUANTIFICATIONS; STATISTICALLY SIGNIFICANT DIFFERENCE;

GENE ENCODING;

AFLATOXIN B1; AFLATOXIN B1 FORMAMIDOPYRIMIDINE 2,3 DIHYDRO 2 (N FORMYL) 2',5',6' TRIAMINO 4' 4' OXY N PYRIMIDYL 3 HYDROXY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

EID: 84857388019     PISSN: 19440049     EISSN: 14645122     Source Type: Journal    
DOI: 10.1080/19440049.2011.647098     Document Type: Article

References (78)

1. Al-Daraji WI, Smith JHF. 2009. Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol. 2:48-64
2. Álvarez MT, Carvajal M, Rojo F, Escobar A. 1999. Comparison between inhibitory indirect ELISA and HPLC methods to quantify free and adducted aflatoxins in human urine. Nat Toxins. 7(4):139-145
3. Álvarez-Bañuelos MT, Carvajal-Moreno M, Ruisánchez- Peón N, Rojo F. 2000. Aductos ADN-Aflatoxina como biomarcador de exposició n en grupos de riesgo de cáncer de hígado [Aflatoxin-DNA adducts as biomarkers of exposure in groups with risk of liver cancer]. Revista Cubana Oncol. 16:35-39
4. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S. 2007. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. International Collaboration of Epidemiological Studies of Cervical Cancer. The Lancet. 370:1609-1621
5. Association of Official Analytical Chemists International [AOAC]. 2005. Natural toxins in official methods of analysis of the Association of Official Analytical Chemists International. In: Horwitz W, editor, 17th ed., Trucksess MW, chapter editor. Chapter 49: Natural toxins. Vol II: Food composition additives; Natural contaminants. Washington (DC): AOAC. p. 1-42
6. Autrup H, Wakhisi J. 1988. Methods for detecting DNA damaging agents in humans: applications in cancer epidemiology and prevention. In: Bartsch H, Hemminki K, O'Neill IK, editors. IARC Scientific Publications No. 89. Lyon (France): IARC. p. 63-66
7. Berger AJ, Baege A, Guillemette T, Deeds J, Meyer R, Disbrow G, Schlegel R. 2002. Insulin-like growth factorbinding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol. 161:603-610
8. Bernatsky S, Hudson M, Pope J, Markland J, Robinson D, Jones N, Docherty P, Abu-Hakima M, Leclerc S, Dunne J, et al. 2009. Canadian Scleroderma Research Group. Reports of abnormal cervical cancer screening tests in systemic sclerosis. Rheumatology (Oxford, UK). 48:149-151
9. Berumen J, Casas L, Segura E, Amezcua JL, García-Carrancá A. 1994. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to retention of E1/E2 genes. Int J Cancer. 56:640-645
10. Berumen J, Ordoñez RM, Lazcano E, Salmerón J, Galván SC, Estrada RA, Yunes E, García-Carrancá A, González-Lira G, Madrigal-de la Campa A. 2001. Asian- American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 93:1325-1330
11. Brown KL, Deng JZ, Iyer RS, Iyer LG, Voehler MW, Stone MP, Harris CM, Harris TM. 2006. Unraveling the aflatoxin - FAPY conundrum: structural basis for differential replicative processing of isomeric forms of the formamidopyrimidine-type DNA adduct of aflatoxin B1. J Am Chem Soc. 128:15188-15199.
12. 1-FAPY adduct in duplex and single-strand DNA. J Am Chem Soc. 131:16096-16107.
13. Busby WF, Wogan GN. 1984. Aflatoxins. Chemical carcinogens. ACS Monogr. 2:945-1136
14. Buss P, Caviezel M, Lutz WR. 1990. Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to AFB1. Carcinogenesis. 11:2133-2135
15. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS, Persing DH. 2002. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 48:1218-1224
16. Calleja-Macias IE, Kalantari M, Bernard HU. 2009. Cholinergic signaling through nicotinic acetylcholine receptors stimulates the proliferation of cervical cancer cells: an explanation for the molecular role of tobacco smoking in cervical carcinogenesis? Intern J Cancer. 124:1090-1096
17. Carvajal M. 2008. Aflatoxin-DNA adducts as biomarkers of cancer. Nature, formation, kinds of AF-DNA adducts, methodology, effects and control. In: Siantar DP, Trucksess MW, Scott PM, Herman EM, editors. Food contaminants. Mycotoxins and food allergens. Chapter 2. ACS Symposium Series 1001. Washington (DC): American Chemical Society. p. 13-55
18. Carvajal M, Mulholland F, Garner RC. 1990. Comparison of the Easi-ExtractTM immunoaffinity concentration procedure with the AOAC CB method for the extraction and quantitation of aflatoxin B1 in raw ground unskinned peanuts. J Chromatogr. 511:379-383
19. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Cheung AF. 2002. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst. 94:1249-1253
20. Chetsanga CJ, Lindahl T. 1979. Release of 7-methylguanine residues whose imidazole rings have been opened from damaged DNA by a DNA glycosylase from Escherichia coli. Nucleic Acids Res. 6:3673-3684
21. Choi MJ, Lee JW, Lee BM. 1996. Comparative assessment of DNA adduct formation, Salmonella mutagenicity, and chromosome aberration assays as short-term tests for DNA damage. J Toxicol Environ Health. 49:271-284
22. Croy RG, Essigmann JM, Reinhold VN, Wogan GN. 1978. Identification of the principal aflatoxin-B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci USA. 75:1745-1749
23. Croy RG, Wogan GN. 1979. Identification of an AFP1- DNA adduct formed in vivo in rat liver. Proc Am Assoc Cancer Res. 20:182.
24. Croy RG, Wogan GN. 1981. Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res. 41:197-203
25. Dizdaroglu M, Kirkali G, Jaruga P. 2008. Formamidopyrimidines in DNA: mechanisms of formation, repair, and biological effects. Free Radical Bio Med. 45:1610-1621
26. Essigmann JM, Croy RG, Bennett RA, Wogan GN. 1982. Metabolic activation of aflatoxin B1 patterns of DNA adduct formation, removal, and excretion in relation to carcinogenesis. Drug Metab Rev. 13:581-602
27. Essigmann JM, Croy RG, Nadzan AM, Busby WF, Reinhold VN, Buchi G, Wogan GN. 1977. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci USA. 74:1870-1874
28. Feng W, Duan X, Liu J, Xiao J, Brown RE. 2009. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol. 2:249-260
29. García MA, Alcántara A. 2002. Guía de validación de métodos analíticos. Ed. Colegio Nacional de Químicos Farmaco-Bió logos, A.C. [Validation guide of analytical methods. Ed. National College of Pharmaco-Biologist Chemists, A.C.]. D.F. México. 1-122
30. Garner RC. 1973. Chemical evidence for the formation of a reactive AB metabolite by hamster liver microsomes. FEBS Lett. 36:261-264
31. 1 binding to cellular macromolecules in vivo and in vitro after peracid oxidation, characterization of the major nucleic adducts. Chem Biol Interact. 26:57-73
32. Garner RC, Ryder R, Montesano R. 1985. Monitoring of aflatoxins in human body fluids and application to field studies. Cancer Res. 45:922-928
33. Gates KS. 2009. An overview of chemical processes that damage cellular DNA: spontaneous hydrolysis, alkylation, and reactions with radicals. Chem Res Toxicol. 22:1747-1760
34. Gates KS, Nooner T, Dutta S. 2004. Biologically relevant chemical reactions of N7-alkylguanine residues in DNA. Chem Res Toxicol. 17:839-856
35. Giuliano AR, Denman C, Guernsey de Zapien J, Navarro Henze JL, Ortega L, Djambazov B, Mendez Brown de Galaz E, Hatch K. 2001. Design and results of the USA- Mexico border human papillomavirus (HPV), cervical dysplasia, and Chlamydia trachomatis study. Rev Panam Salud Pública. 9(3):172-181
36. Goto T. 1990. Comparison of some immunological aflatoxin analysis methods. Rep Nat Food Res Inst. 54:35-43
37. Groopman JD, Donahue KF. 1988. Aflatoxin, a human carcinogen: determination in foods and biological samples by monoclonal antibody affinity chromatography. J Assoc Off Anal Chem. 71:861-867
38. Groopman JD, Kensler TW. 1987. The use of monoclonal antibody affinity column for assessing DNA damage and repair following exposure to aflatoxins. Pharmacol Therapeut. 34:321-334
39. Groopman JD, Zarba A. 1991. Immunoaffinity-based monitoring of human exposure to aflatoxins in China and Gambia. In: Vanderlaan M, Stanker LH, Watkins BE, Roberts DW, editors. Immunoassays for trace chemical analysis: monitoring toxic chemicals in humans, foods and the environment. Washington (DC): American Chemical Society (ACS). p. 207-214
40. Guengerich FP, Mundkowski RG, Voehler M, Kadlubar FF. 1999. Formation and reactions of N7- aminoguanosine and derivatives. Chem Res Toxicol. 12:906-916
41. Harrison JC, Carvajal M, Garner RC. 1991. Immunological detection of AFB1-DNA and AFB1-serum albumin adducts in rat and human tissues. In: Garner RC, Farmer PB, Steel GT, Wright AS, editors. Human carcinogen exposure: biomonitoring and risk assessment. Oxford (UK): Oxford University Press. p. 255-265
42. Harrison JC, Carvajal M, Garner RC. 1993. Does aflatoxin exposure in the United Kingdom constitute a cancer risk? Environ Health Perspect. 99:99-105
43. Harrison JC, Garner RC. 1991. Immunochemical and HPLC detection of aflatoxin adducts in human tissues after an acute poisoning incident in S.E. Asia. Carcinogenesis. 12:741-743
44. Hernández-Avila M, Lazcano-Ponce EC, Berumen-Campos J, Cruz-Valdez A, Alonso de Ruiz PP, González-Lira G. 1997. Human papillomavirus 16-18 infection and cervical cancer in México: a case-control study. Arch Med Res. 28:265-271
45. Hertzog PJ, Linday Smith JR, Garner RC. 1982. Characterization of the imidazole ring opened forms of the trans-8,9-dihydroxy-8-(7-guanyl)-9-hydroxy aflatoxin B1. Carcinogenesis. 3:723-725
46. Horwitz W. 1982. Evaluation of analytical methods used for regulations of foods and drugs. Anal Chem. 54(1):67A-76A.
47. Horwitz W. 1995. Protocol for the design, conduct and interpretation of method-performance studies. Pure Appl Chem. 67:331-343
48. Hsieh LL, Hsieh TT. 1993. Detection of aflatoxin B1-DNA adducts in human placenta and cord blood. Cancer Res. 53:1278-1280
49. Humphreys WG, Guengeric FP. 1991. Structure of formamidopyrimidine adducts as determined by NMR using specifically 15N-labeled guanosine. Chem Res Toxicol. 4:632-636
50. IARC. 2002. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. Monographs on the Evaluation of Carcinogenic Risks to Humans, 82. Lyon (France): International Agency for Research on Cancer (IARC). p. 171.
51. Lazcano Ponce E, Hernández-Ávila M, López-Carrillo L, Alonso de Ruíz P, González-Lira G, Torres-Lobatón A, Romieu I. 1995. Factores de riesgo reproductivo e historia de vida sexual asociados a cáncer cervical en una muestra de mujeres de la Ciudad de México [Factors of reproductive risk and sexual life history associated with cervical cancer in a sample of women of Mexico City]. Rev Invest Clín(México). 47:377-385
52. Lee HS, Sarosi I, Vyas GN. 1989. Aflatoxin B1 formamidopyrimidine adducts in human hepatocarcinogenesis: a preliminary report. Gastroenterology. 97:1281-1287
53. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. 2008. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 113:1980-1993
54. Mao H, Deng JZ, Wang F, Harris TM, Stone MP. 1998. An intercalated and thermally stable FAPY adduct of Aflatoxin B1 in a DNA duplex: structural refinement from 1H NMR. Biochemistry. 37:4374-4387
55. Martin CM, Garner RC. 1977. Aflatoxin B1 oxide generated by chemical or enzymatic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids. Nature. 267:863-865
56. Munk BH, Burrows CJ, Schlegel HB. 2007. Exploration of mechanisms for the transformation of 8-hydroxy guanine radical to FAPyG by density functional theory. Chem Res Toxicol. 20:432-444
57. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:518-527
58. Olsen JH, Dragsted I, Autrup H. 1988. Cancer risk and occupational exposure to aflatoxins in Denmark. Br J Cancer. 58:236-250
59. Pier AC, Fichtner RE, Cysewski SJ. 1977. Effect of aflatoxin on the cellular immune system. Ann Nutr Aliment. 31(4-6):781-788
60. Poirier MC. 1997. DNA adducts as exposure biomarkers and indicators of cancer risk. Environ Health Perspect. 105:907-912
61. Reshmi G, Pillai MR. 2008. Beyond HPV: oncomirs as new players in cervical cancer. FEBS Lett. 582:4113-4116
62. 1: measurement of carcinogen adducts. In: Vanderlaan M, Stanker LH, Watkins BE, Roberts DW, editors. Series analytic: immunoassays for trace chemical analysis: monitoring toxic chemicals in humans, food, and the environment. ACS Symposium series, 451. Washington (DC): American Chemical Society. p. 229-245
63. Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, Shrivastava S, Dinshaw K. 2002. HPV 16/ 18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol. 86:157-162
64. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. The Lancet. 370:890-907
65. Sharman M, Patey AL, Gilbert J. 1989. Application of an immunoaffinity column sample clean-up to the determination of aflatoxinM1 in cheese. J Chromatogr. 474:457-461
66. Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM. 2002. The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci USA. 99:6655-6660
67. Sotomayor RE, Sahu S, Washington M, Hinton DM, Chou M. 1999. Temporal patterns of DNA adduct formation and glutathione S-transferase activity in the testes of rats fed aflatoxin B1: a comparison with patterns in the liver. Environ Mol Mutagen. 33:293-302
68. Subramanya D, Grivas PD. 2008. HPV and cervical cancer: updates on an established relationship. Postgrad Med. 120:7-13
69. 1. Cancer Res. 35:3811-3823
70. Thompson M. 2000. Towards a unified model of errors in analytical measurement. Analyst. 125:2020-2025
71. Thompson M, Ellison SLR, Fajgelj A, Willetts P, Wood R. 1999. Harmonised guidelines for the use of recovery information in analytical measurement. Pure Appl Chem. 71:337-348
72. Thompson M, Wood R. 1995. Harmonized guidelines for internal quality control in analytical chemistry laboratories. Pure Appl Chem. 67:649-666
73. Tovar JM, Bazaldua OV, Vargas L, Reile E. 2008. Human papillomavirus, cervical cancer, and the vaccines. Postgrad Med. 120:109-111
74. Wild CP, Jansen LAM, Cova L, Montesano R. 1993. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect. 99:115-122
75. Wild CP, Pisani P. 1998. Carcinogen DNA and protein adducts as biomarkers of human exposure in environmental cancer epidemiology. Cancer Detect Prev. 22:273-283
76. Wogan GN. 1976. The induction of liver cell cancer by chemicals. In: Cameron HM, Linsell DA, Warwick GP, editors. Liver cell cancer. Amsterdam: Elsevier/North Holland. p. 121-151
77. Wood GM, Mann PJ. 1987. Evaluation of total aflatoxin Easi-Extract™ columns for the analysis of aflatoxins in peanuts. Technical Note No. 63, Leather-head Food Research Association. Woodworth CD. 2002. HPV innate immunity. Frontiers Biosci Virtual Lib. 7:d2058-d2071 (electronic resource).
78. Workowski KA, Levine WC, Wasserheit JN. 2002. US Centers for Disease Control and Prevention guidelines for the treatment of sexually transmitted diseases: an opportunity to unify clinical and public health practice. Ann Intern Med. 137:255-262.